242 related articles for article (PubMed ID: 24252778)
1. The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.
Pajtler KW; Weingarten C; Thor T; Künkele A; Heukamp LC; Büttner R; Suzuki T; Miyata N; Grotzer M; Rieb A; Sprüssel A; Eggert A; Schramm A; Schulte JH
Acta Neuropathol Commun; 2013 May; 1():19. PubMed ID: 24252778
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of KDM1A suppresses tumour migration and invasion by epigenetically regulating the TIMP1/MMP9 pathway in papillary thyroid cancer.
Zhang W; Sun W; Qin Y; Wu C; He L; Zhang T; Shao L; Zhang H; Zhang P
J Cell Mol Med; 2019 Aug; 23(8):4933-4944. PubMed ID: 31211500
[TBL] [Abstract][Full Text] [Related]
3. Histone demethylase KDM1A represses inflammatory gene expression in preadipocytes.
Hanzu FA; Musri MM; Sánchez-Herrero A; Claret M; Esteban Y; Kaliman P; Gomis R; Párrizas M
Obesity (Silver Spring); 2013 Dec; 21(12):E616-25. PubMed ID: 23595969
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
Jiang Q; Stachelscheid J; Bloehdorn J; Pacholewska A; Aszyk C; Grotenhuijs F; Müller T; Onder O; Wagle P; Herling CD; Kleppe M; Wang Z; Coombes KR; Robrecht S; Dalvi PS; Plosnita B; Mayer P; Abruzzo LV; Altmüller J; Gathof B; Persigehl T; Fischer K; Jebaraj B; Rienhoff HY; Ecker R; Zhao Y; Bruns CJ; Stilgenbauer S; Elenitoba-Johnson K; Hallek M; Schweiger MR; Odenthal M; Vasyutina E; Herling M
Blood; 2023 Jul; 142(1):44-61. PubMed ID: 37023372
[TBL] [Abstract][Full Text] [Related]
5. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.
Sareddy GR; Viswanadhapalli S; Surapaneni P; Suzuki T; Brenner A; Vadlamudi RK
Oncogene; 2017 Apr; 36(17):2423-2434. PubMed ID: 27893719
[TBL] [Abstract][Full Text] [Related]
6. Targeting Group 3 Medulloblastoma by the Anti-PRUNE-1 and Anti-LSD1/KDM1A Epigenetic Molecules.
Bibbò F; Asadzadeh F; Boccia A; Sorice C; Bianco O; Saccà CD; Majello B; Donofrio V; Bifano D; De Martino L; Quaglietta L; Cristofano A; Covelli EM; Cinalli G; Ferrucci V; De Antonellis P; Zollo M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612726
[TBL] [Abstract][Full Text] [Related]
7. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
8. KDM1 is a novel therapeutic target for the treatment of gliomas.
Sareddy GR; Nair BC; Krishnan SK; Gonugunta VK; Zhang QG; Suzuki T; Miyata N; Brenner AJ; Brann DW; Vadlamudi RK
Oncotarget; 2013 Jan; 4(1):18-28. PubMed ID: 23248157
[TBL] [Abstract][Full Text] [Related]
9. Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma.
Yi J; Shi X; Xuan Z; Wu J
Cancer Lett; 2021 Feb; 499():188-200. PubMed ID: 33253789
[TBL] [Abstract][Full Text] [Related]
10. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
Harris WJ; Huang X; Lynch JT; Spencer GJ; Hitchin JR; Li Y; Ciceri F; Blaser JG; Greystoke BF; Jordan AM; Miller CJ; Ogilvie DJ; Somervaille TC
Cancer Cell; 2012 Apr; 21(4):473-87. PubMed ID: 22464800
[TBL] [Abstract][Full Text] [Related]
11. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
Murray-Stewart T; Woster PM; Casero RA
Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
[TBL] [Abstract][Full Text] [Related]
12. Further insights into the SAR of α-substituted cyclopropylamine derivatives as inhibitors of histone demethylase KDM1A.
Pieroni M; Annunziato G; Azzali E; Dessanti P; Mercurio C; Meroni G; Trifiró P; Vianello P; Villa M; Beato C; Varasi M; Costantino G
Eur J Med Chem; 2015 Mar; 92():377-86. PubMed ID: 25585008
[TBL] [Abstract][Full Text] [Related]
13. Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable
Mascaró C; Ortega A; Carceller E; Ruiz Rodriguez R; Ciceri F; Lunardi S; Yu L; Hilbert M; Maes T
J Biol Chem; 2019 May; 294(20):8311-8322. PubMed ID: 30804215
[TBL] [Abstract][Full Text] [Related]
14. MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.
Althoff K; Beckers A; Odersky A; Mestdagh P; Köster J; Bray IM; Bryan K; Vandesompele J; Speleman F; Stallings RL; Schramm A; Eggert A; Sprüssel A; Schulte JH
Int J Cancer; 2013 Sep; 133(5):1064-73. PubMed ID: 23400681
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL
Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A.
Vianello P; Botrugno OA; Cappa A; Ciossani G; Dessanti P; Mai A; Mattevi A; Meroni G; Minucci S; Thaler F; Tortorici M; Trifiró P; Valente S; Villa M; Varasi M; Mercurio C
Eur J Med Chem; 2014 Oct; 86():352-63. PubMed ID: 25173853
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
18. miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A.
Yang H; Li Q; Zhao W; Yuan D; Zhao H; Zhou Y
FEBS Lett; 2014 Jan; 588(1):192-7. PubMed ID: 24316513
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
Cortez V; Mann M; Tekmal S; Suzuki T; Miyata N; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Vadlamudi RK
Breast Cancer Res; 2012 Jul; 14(4):R108. PubMed ID: 22812534
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of lysine-specific demethylase 1A suppresses neointimal hyperplasia by targeting bone morphogenetic protein 2 and mediating vascular smooth muscle cell phenotype.
Zhang X; Huang T; Zhai H; Peng W; Zhou Y; Li Q; Yang H
Cell Prolif; 2020 Jan; 53(1):e12711. PubMed ID: 31737960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
